Car T-Cell Therapy
Q&A: CAR T cells may represent 'more thorough therapeutic approach' for glioblastoma
Chimeric antigen receptor T cells have emerged “as a promising therapeutic avenue” for the treatment of glioblastoma, though various factors still limit its efficacy, according to a review published in Neurology.
FDA grants priority review to ciltacabtagene autoleucel for advanced multiple myeloma
The FDA granted priority review to ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory multiple myeloma, according to the agent’s manufacturer.
FDA grants fast track designation to CAR T-cell therapy for thyroid cancer
The FDA granted fast track designation to AIC100, a chimeric antigen receptor T-cell therapy, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer, according to the agent’s manufacturer.
Treatment with gene-edited cell therapies not associated with subsequent cancer risk
Patients with cancer who received genetically modified immune effector cells did not demonstrate increased risk for developing subsequent malignancies, according to results of a retrospective study.
Report: CAR-T for multiple myeloma clinically beneficial, but value low at current cost
An independent panel unanimously agreed that chimeric antigen receptor T-cell therapy provides clinical benefit superior to the current standard of care for patients with relapsed or refractory multiple myeloma.
CAR-T pioneer receives American Society of Gene and Cell Therapy’s highest honor
Michel Sadelain, MD, PhD, will receive this year’s Outstanding Achievement Award from the American Society of Gene and Cell Therapy for his research on chimeric antigen receptors.
CAR T-cell therapy, bispecific T-cell engagers, other exciting treatments in multiple myeloma
Maung Myo Htut, MD, associate clinical professor in the division of multiple myeloma within the department of hematology and hematopietic cell transplantation at City of Hope, discussed treatment developments in multiple myeloma, including exciting data from ASH 2020, the role of CAR T-cell therapy, autologous hematopoietic stem cell transplant, consolidation therapy and more.
Access to CAR T-cell therapy faces regional challenges
The additional distance that Americans must travel to receive chimeric antigen receptor T-cell therapy compared with other cancer treatments varies greatly by region, according to a study by health care consulting firm Avalere Health.
Top in hem/onc: CAR-T for diffuse midline gliomas, new endometrial cancer therapy
Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for diffuse midline gliomas during the virtual American Association for Cancer Research Annual Meeting.
Research grant funds investigations into novel immuno-cellular therapy strategies
Frederick L. Locke, MD, has been awarded a clinical research grant by The Leukemia & Lymphoma Society in collaboration with Moffitt Cancer Center.